Formation of malonaldehyde in the presence of probucol, an antiatherosclerosis drug

Food and Chemical Toxicology

Volumn 36, Issue 9-10, 1998, Pages 841-847

  Miyake, T ^a   Shibamoto, T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood plasma oxidation; Malonaldehyde; Probucol

Indexed keywords

ASCORBIC ACID; MALONALDEHYDE; PROBUCOL;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; DRUG HYDROLYSIS; DRUG OXIDATION; GAS CHROMATOGRAPHY; HORSE; LIPID OXIDATION; NONHUMAN; OXIDATION; PLASMA;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; DRUG INTERACTIONS; HORSES; HYDROGEN PEROXIDE; IRON; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; PROBUCOL;

ANIMALIA; EQUUS CABALLUS;

EID: 0031656826     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(98)00062-3     Document Type: Article

References (31)

1. Aoyama S. and Iwakami M. (1965) On the role of fatty acid peroxides in atherosclerosis. Japanese Heart Journal 6, 128-143.
2. Basu A. K. and Marnett L. J. (1983) Unequivocal demonstration that malonaldehyde is a mutagen. Carcinogenesis 4, 331-333.
3. Bird R. P. and Draper H. H. (1980) Effect of malonaldehyde and acetaldehyde on cultured mammalian cells: Growth, morphology, and synthesis of macromolecules. Journal of Toxicology and Environmental Health 6, 811-823.
4. Bothner-By A. A. and Jarris R. K. (1965) Conformational preferences in malonaldehyde and acetylacetaldehyde enols investigated by nuclear magnetic resonance. Journal of Organic Chemistry 30, 254-257.
5. Brown M. S. and Goldstein J. L. (1976) Receptor-mediated control of metabolism. Science 191, 150-154.
6. Burton G. W. and Ingold K. U. (1984) β-Carotene: An unusual type of lipid antioxidant. Science 22, 569-573.
7. Carew E. T., Schwenke C. D. and Steinberg D. (1987) Antiatherogenic effect of probucol unrelated to its hypochoresterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proceedings of the National Academy of Sciences of the U.S.A. 84, 7725-7729.
8. Chico K. and Tappel A. (1969) Inactivation of ribonuclease and other enzymes by peroxidized lipids and by malonaldehyde. Biochemistry 8, 2827-2832.
9. Crandon J. H., Lund C. C. and Dill D. B. (1940) Experimental human scurvy. New England Journal of Medicine 223, 353-369.
10. Folgelman A. M., Schecter I., Seager J., Hokom M., Child J. S. and Edwards P. A. (1980) Malonaldehyde alteration of low-density lipoproteins leads to cholesterol ester accumulation in human monocyte-macrophages. Proceedings of the National Academy of Sciences of the U.S.A. 77, 2214-2218.
11. Gey K. F. (1986) On the antioxidant hypothesis with regard to arteriosclerosis. Bibliotheca Nutritio et Dieta 37, 53-91.
12. Glavind J., Hartmann S., Clemmensen J., Jessen K. E. and Dam H. (1952) Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathologica et Microbiologica Scandinavica 30, 1-6.
13. Henriksen T., Mahoney E. M. and Steinberg D. (1981) Enhanced macrophage degradation of low-density lipoproteins previously incubated with cultured endothelial cells: Recognition by the receptors for acetylated low-density lipoproteins. Proceedings of the National Academy of Sciences of the U.S.A. 78, 6499-6503.
14. Henriksen T., Mahoney E. M. and Steinberg D. (1983) Enhanced macrophage degradation of biological modified low-density lipoprotein. Atherosclerosis 3, 149-159.
15. Lacombe A., Kermasha S., van de Voort R. F. and Mills L. B. (1990) Preparation and purification of malonaldehyde sodium salt. Journal of Agricultural and Food Chemistry 38, 418-423.
16. Lam C. W., Casanova M. and Heck H. D. (1986) Decreased extractability of DNA from proteins in the rat nasal mucosa after acetaldehyde exposure. Fundamental and Applied Toxicology 6, 541-550.
17. Mahley R. W., Innerarity T. L., Weisgraber K. H. and Oh S. Y. (1979) Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective modification of lysine residues of the apoproteins. Journal of Clinical Investigation 64, 743-750.
18. 14C-labeled tetraethoxypropane to malonaldehyde. Analytical Biochemistry 99, 458-463.
19. Miyake T., Hagiwara Y., Hagiwara H. and Shibamoto T. (1998) Functional Foods: Overview and Disease Prevention, ed. T. Shibamoto. ACS, Washington, DC.
20. Munkres K. D. (1976) Aging of neurospora crassa. IV. Induction of senescence in wild type by dietary amino acid analogs and reversal by antioxidants and membrane stabilizers. Mechanisms of Aging and Development 5, 171-191.
21. National Cholesterol Education Program (1991) Report of the expert panel on population strategies for blood cholesterol reduction Circulation 83, 2154-2232.
22. Parthasarathy S., Steinbrecher U. P., Barnett J., Witztum J. L. and Steinberg D. (1985) The essential role of phospholipase A2 activity in endothelial cell-induced modification of low-density lipoprotein. Proceedings of the National Academy of Sciences of the U.S.A. 82, 3000-3004.
23. Reiss U., Tappel A. L. and Chio K. S. (1972) DNA-malonaldehyde reaction: Formation of fluorescent products. Biochemical and Biophysical Research Communications 48, 921-926.
24. Retsky K. L., Freeman M. W. and Frei B. (1993) Ascorbic acid oxidation product(s) protect human low-density lipoprotein against atherogenic modification. Journal of Biological Chemistry 268, 1304-1309.
25. Schecter I., Folgelman A. M., Haberland M. E., Seager J., Hokom M., Child J. S. and Edwards P. A. (1981) The metabolism of native and malonaldehyde-altered low-density lipoproteins by human monocyte-macrophages. Journal of Lipid Research 22, 63-71.
26. Shamberger R. J., Corlett C. L., Beaman K. D. and Kasten B. L. (1979) Antioxidants reduce the mutagenic effect of malonaldehyde and β-propiolactone Part IX, Antioxidants and cancer. Mutation Research 66, 349-355.
27. Steinberg D., Parthasarathy S., Carew E. T., Khoo C. J. and Witztum L. J. (1989) Beyond cholesterol modifications of low-density lipoprotein that increase its athrogenicity. New England Journal of Medicine 320, 915-924.
28. Steinbrecher U. P., Parthasarathy S., Leake D. S., Witztum J. L. and Steinberg D. (1984) Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proceedings of the National Academy of Sciences of the U.S.A. 81, 3883-3887.
29. Stocker R., Bowry V. W. and Fre B. (1991) Ubiquinol-10 protects human low-density lipoprotein more efficiently against lipid peroxidation than does (-tocopherol. Proceedings of the National Academy of Sciences of the U.S.A. 88, 1646-1650.
30. Umano K., Dennis K. J. and Shibamoto T. (1988) Analysis of free malonaldehyde in photoirradiated corn oil and beef fat via a pyrazole derivative. Lipids 23, 811-814.
31. Weisburger J. H., Marquardt H., Mower J. F., Hirota N., Mori H. and Williams G. (1980) Inhibition of carcinogenesis: Vitamin C and the prevention of gastric cancer. Preventive Medicine 9, 352-371.